Renal cell carcinoma (RCC) is one of the most common urological malignancies and is a leading cause of global mortality. The main pathological type of RCC is known as clear cell renal cell carcinoma (ccRCC) which accounts for the majority of RCC-related deaths due to greater malignant and invasive features, poorer survival rate and prognosis. There have been evolving advances in the field of targeted and therapies to improve the survival rate of ccRCC. However, for patients with high-grade and advanced-stage ccRCC, the survival rate and prognosis is low. Therefore, further studies are required to identify potential novel biomarkers and alternative therapeutic targets to improve the prognosis of RCC and ccRCC patients.
Long non-coding RNAs (lncRNAs) are classified as a class of non-coding RNA transcripts with over 200 nucleotides. They have been found to play a significant role in the biological behaviour of various cancers by the regulation of several physiological and molecular processes which contribute to proliferation, invasion and metastasis. Studies have found specific lncRNAs play a role in RCC including low expression of lncRNA B7H4 as a predictor of survival in RCC patients. Other studies have also identified specific lncRNAs that can act as a potential biomarkers to predict the survival rate and prognosis for RCC and ccRCC patients, however further studies are required to establish and identify the distant metastasis-related lncRNA signature and its potential regulatory network.
The goal of this Research Topic is to explore how long non-coding RNAs impact the survival and prognosis of renal carcinoma patients in addition to exploring how it impacts the metastatic stage of the disease. We welcome Original Research Articles, Review Articles and Systematic Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Renal cell carcinoma (RCC) is one of the most common urological malignancies and is a leading cause of global mortality. The main pathological type of RCC is known as clear cell renal cell carcinoma (ccRCC) which accounts for the majority of RCC-related deaths due to greater malignant and invasive features, poorer survival rate and prognosis. There have been evolving advances in the field of targeted and therapies to improve the survival rate of ccRCC. However, for patients with high-grade and advanced-stage ccRCC, the survival rate and prognosis is low. Therefore, further studies are required to identify potential novel biomarkers and alternative therapeutic targets to improve the prognosis of RCC and ccRCC patients.
Long non-coding RNAs (lncRNAs) are classified as a class of non-coding RNA transcripts with over 200 nucleotides. They have been found to play a significant role in the biological behaviour of various cancers by the regulation of several physiological and molecular processes which contribute to proliferation, invasion and metastasis. Studies have found specific lncRNAs play a role in RCC including low expression of lncRNA B7H4 as a predictor of survival in RCC patients. Other studies have also identified specific lncRNAs that can act as a potential biomarkers to predict the survival rate and prognosis for RCC and ccRCC patients, however further studies are required to establish and identify the distant metastasis-related lncRNA signature and its potential regulatory network.
The goal of this Research Topic is to explore how long non-coding RNAs impact the survival and prognosis of renal carcinoma patients in addition to exploring how it impacts the metastatic stage of the disease. We welcome Original Research Articles, Review Articles and Systematic Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
